300244.SHE Zhejiang DiAn Diagnostics Co
- Market cap
- CNY 12.6B
- P/E
- 25.5x
- P/B
- 1.88x
- ROE
- 9.6%
- Dividend yield
- 2.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300244.SHE undervalued?
Graham number300244.SHE trades 46.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang DiAn Diagnostics Co fundamental analysis
No fundamental analysis for Zhejiang DiAn Diagnostics Co yet.
Zhejiang DiAn Diagnostics Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang DiAn Diagnostics Co
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated pathology slide staining system, genotyping DNA test kit, human papillomavirus …
Full company profileZhejiang DiAn Diagnostics Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang DiAn Diagnostics Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.82B | 5.00B | 6.97B | 8.45B | 10.6B | 13.1B | 20.3B | 13.4B | 12.2B | 10.1B | 9.88B |
| Gross Profit | 1.20B | 1.66B | 2.36B | 2.70B | 4.05B | 4.98B | 7.47B | 4.15B | 3.38B | 2.87B | 3.00B |
| Operating Income | 415M | 593M | 721M | 775M | 1.32B | 1.84B | 2.82B | 842M | -31.1M | 741M | 1.09B |
| EBITDA | 472M | 656M | 1.07B | 1.26B | 2.20B | 2.47B | 4.25B | 1.47B | 928M | 874M | 1.21B |
| Net Income | 263M | 350M | 389M | 347M | 803M | 1.16B | 1.43B | 307M | -357M | 44.1M | 643M |
| EPS | 0.48 | 0.64 | 0.71 | 0.56 | 1.29 | 1.87 | 2.30 | 0.49 | -0.58 | 0.07 | 1.03 |
| Balance Sheet | |||||||||||
| Total Assets | 5.72B | 7.39B | 10.7B | 10.8B | 12.4B | 15.6B | 21.1B | 17.9B | 15.8B | 14.4B | 13.7B |
| Total Liabilities | 3.17B | 4.44B | 5.96B | 5.61B | 6.37B | 8.12B | 11.6B | 8.03B | 7.02B | 5.82B | 4.89B |
| Shareholders' Equity | 2.09B | 2.35B | 3.68B | 3.98B | 4.70B | 5.84B | 7.45B | 7.57B | 6.56B | 6.44B | 6.72B |
| Cash & Short-term Investments | 539M | 755M | 1.71B | 1.60B | 2.05B | 2.62B | 4.65B | 3.39B | 2.21B | 2.11B | 971M |
| Total Debt | 1.75B | 3.13B | 3.61B | 3.37B | 3.76B | 4.37B | 6.02B | 3.55B | 2.40B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 132M | 38.5M | 373M | 483M | 1.55B | 1.32B | 1.64B | 1.92B | 1.21B | 2.03B | - |
| Capital Expenditure | 317M | 382M | 457M | 411M | 476M | 589M | 948M | 702M | 363M | 285M | 228M |
| Free Cash Flow | -185M | -344M | -83.4M | 71.7M | 1.07B | 728M | 692M | 1.22B | 844M | 1.74B | 871M |
| Ratios | |||||||||||
| ROE | 12.6% | 14.9% | 10.6% | 8.7% | 17.1% | 19.9% | 19.3% | 4.1% | -5.4% | 0.7% | 9.6% |
| ROA | 4.6% | 4.7% | 3.6% | 3.2% | 6.5% | 7.5% | 6.8% | 1.7% | -2.3% | 0.3% | 4.7% |
| Net Profit Margin | 6.9% | 7.0% | 5.6% | 4.1% | 7.5% | 8.9% | 7.1% | 2.3% | -2.9% | 0.4% | 6.5% |
| Debt to Equity | 0.84x | 1.33x | 0.98x | 0.85x | 0.80x | 0.75x | 0.81x | 0.47x | 0.37x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang DiAn Diagnostics Co dividends
- Dividend yield
- 2.03%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 580.7%
- Ex-dividend date
- Jun 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 256M | 0.41 | 580.7% |
| 2024 | CNY 576M | 0.94 | - |
| 2023 | CNY 301M | 0.48 | 97.8% |
| 2022 | CNY 83.8M | 0.13 | 5.8% |
| 2021 | CNY 80.7M | 0.13 | 6.9% |
| 2020 | CNY 79.4M | 0.13 | 9.9% |
| 2019 | CNY 15.5M | 0.02 | 4.5% |
| 2018 | CNY 175M | 0.32 | 44.9% |
| 2017 | CNY 89.2M | 0.16 | 25.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 18:10 on May 9, 2016.
Who owns Zhejiang DiAn Diagnostics Co
- Insiders 29.42%
- Institutions 7.42%
- Public & others 63.16%
- Shares outstanding 625M
- Free float 435M
Zhejiang DiAn Diagnostics Co company profile
- Company name
- Zhejiang DiAn Diagnostics Co
- Ticker
- 300244.SHE
- ISIN
- CNE1000015N1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 19, 2011
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 7,462
- Fiscal year end
- December
- Address
- Building 2, Hangzhou, China, 310030
- Phone
- 86 57 1580 85608
- Website
- dazd.cn
About Zhejiang DiAn Diagnostics Co
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated pathology slide staining system, genotyping DNA test kit, human papillomavirus nucleic acid detection kit, PCR system and detection system, and virus collection and preservation system; and multi-omics platform services. It also provides DP-TOF nucleic acid mass spectrometry solutions, including mass spectroscopy system, automatic sample processing system, respiratory pathogens multiple detection kit, and nucleic acid sample pretreatment reagent kit; and forensic drug testing products comprises diangio, hair drug trace tester and detector, and saliva and urine drug testing product series. In addition, the company offers diagnostic product supply, medical testing services, supply chain optimization, digital operation management, laboratory quality system construction, and professional cold chain logistics services. Further, it is involved in the research and development of diagnostic products; and vitro diagnostic reagents, as well as forensic identification, health management, and other fields. The company was formerly known as Zhejiang DIAN Diagnostics Co., Ltd. and changed its name to Dian Diagnostics Group Co.,Ltd. in November 2017. Dian Diagnostics Group Co.,Ltd. was founded in 1996 and is based in Hangzhou, China.
Zhejiang DiAn Diagnostics Co management
5- Mr. Haibin Chen B.S. (EMBA)GM & Chairman of the Board · born 1969
- Mr. Dekang ZhaoDeputy GM, Head of Accounting Agency, Financial Manager & Director · born 1968
- Mr. Sanhui GuoDeputy General Manager & Director · born 1975
- Mr. Weiyan WuDeputy General Manager · born 1971
- Ms. Jun TaoDeputy GM & Secretary of the Board · born 1981